Augmedix vs Eli Lilly
Side-by-side comparison of AI visibility scores, market position, and capabilities
San Francisco medical documentation company combining AI transcription with remote human scribes to produce EHR notes from physician-patient encounters in real time via smartphone or Glass.
About
Augmedix is a San Francisco-based medical documentation company that combines AI transcription technology with remote human scribes to document physician-patient encounters in real time, producing complete EHR notes that physicians review and sign. Physicians wear Google Glass or use a smartphone to stream audio and video of patient encounters to Augmedix's platform, where remote scribes observe and document the visit, supported by AI tools that transcribe speech and suggest note structures. This hybrid AI-plus-human model enables documentation quality and customization that pure AI solutions struggle to achieve for complex clinical encounters, while still dramatically reducing the time physicians spend on documentation. Augmedix serves large health systems and multispecialty groups, with customer deployments across hundreds of physicians. The company went public via merger with LifeSci Acquisition in 2020 and was subsequently acquired by Nuvation Bio. Augmedix competes with Nuance DAX, Suki, and traditional medical transcription services in the clinical documentation market.
Indianapolis global pharma (NYSE: LLY) at $45B 2024 revenue (+32%); first healthcare company to $1T market cap (Nov 2024) with Mounjaro/Zepbound tirzepatide (37% revenue) and oral GLP-1 orforglipron Phase 3 competing with Novo Nordisk.
About
Eli Lilly and Company is an Indianapolis, Indiana-based global pharmaceutical company — publicly traded on the New York Stock Exchange (NYSE: LLY) as an S&P 500 Dow Jones Industrial Average component — that in November 2024 became the world's most valuable pharmaceutical company with a historic $1 trillion market capitalization, the first healthcare company ever to reach this milestone. In fiscal year 2024, Lilly achieved approximately $45 billion in revenue, representing 32% growth from 2023, driven by blockbuster GLP-1 medications tirzepatide (Mounjaro for type 2 diabetes and Zepbound for obesity and obstructive sleep apnea), which together accounted for 37% of 2024 revenues. Other key products include Trulicity (dulaglutide, 12% of revenue), Humalog (insulin lispro, 5%), and Kisunla (donanemab), the first new Alzheimer's therapy approved for early symptomatic disease in 2024. An oral GLP-1 pill (orforglipron) is in Phase 3 clinical trials. CEO David Ricks has led the company since 2017. Founded in 1876 by Colonel Eli Lilly in Indianapolis, the company pioneered mass production of Jonas Salk's polio vaccine in 1955 and was among the first to produce human insulin using recombinant DNA technology.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.